The way people manage diabetes is changing faster than ever before. The global diabetes care devices market is projected to grow from $40.8 billion in 2025 to $76.4 billion by 2034, expanding at a rate of 7.26% annually . This explosive growth reflects a fundamental shift in how patients and doctors approach blood sugar management, with advanced technologies making daily diabetes care more convenient, accurate, and personalized than ever before.

The driving force behind this expansion is straightforward: diabetes is becoming more common worldwide. Rising obesity levels, sedentary lifestyles, unhealthy eating patterns, and an aging population are all contributing to higher diabetes rates globally. As more people receive diabetes diagnoses, the demand for effective monitoring and management tools has skyrocketed, pushing innovation across the entire device industry .

What New Diabetes Devices Are Changing the Game?

The past year has seen a remarkable wave of device approvals and launches that are making diabetes management less burdensome. In August 2024, Medtronic received FDA approval for the Simplera continuous glucose monitor (CGM), a disposable, all-in-one device that is half the size of previous models and requires no overtape for securing it to the skin . Even more impressive, the Eversense 365 received FDA clearance in September 2024 as an integrated CGM system that works for an entire year with a single sensor, compared to traditional CGMs that last only 10 to 14 days .

In April 2025, Dexcom released the G7 15-Day sensor with extended wear time and enhanced accuracy . Meanwhile, Medtronic expanded the indications for its MiniMed 780G system in July 2025 to include children as young as 2 years old, pregnant women, and people with type 2 diabetes requiring insulin . These innovations address real pain points that patients face: the hassle of frequent sensor changes, the discomfort of adhesive tape, and the need for devices that work across different age groups and diabetes types.

Perhaps most notably, in August 2025, Signos launched the first FDA-cleared, over-the-counter glucose monitoring system designed specifically for weight management . This system integrates Dexcom's Stelo glucose biosensor with an artificial intelligence platform that provides personalized, real-time insights into how food, activity, stress, and sleep affect metabolic health . This represents a significant shift: glucose monitoring is no longer exclusively for people with diagnosed diabetes.

How Are Insulin Delivery Devices Becoming More Accessible?

Insulin delivery has also seen major innovations aimed at affordability and ease of use. In May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN, a user-filled insulin pen that is compatible with standard insulin vials . This device provides an affordable alternative to traditional disposable pens, addressing a critical barrier for many patients: cost. Additionally, smart insulin pens and insulin pumps continue to evolve, offering more precise dosing and better integration with digital health platforms .

Steps to Understanding Your Diabetes Device Options

• Blood Glucose Monitoring Devices: These include traditional blood glucose meters that measure glucose from a small blood sample, as well as wearable and non-wearable options that provide flexibility depending on your lifestyle and preferences .
• Continuous Glucose Monitors (CGMs): These devices provide real-time glucose readings throughout the day and night, eliminating the need for frequent finger pricks and offering insights into how your body responds to food, activity, and stress .
• Insulin Delivery Systems: Options range from traditional insulin pens and syringes to advanced insulin pumps and smart pens that deliver precise doses and can sync with glucose monitoring systems for automated insulin adjustments .

When choosing a device, working closely with your healthcare provider is essential. The right device depends on several factors, including the severity of your diabetes, your lifestyle, other medical conditions you may have, and your personal preferences . Not all devices are suitable for everyone, and your doctor will customize recommendations based on your specific needs.

Where Is the Device Market Growing Fastest?

North America currently dominates the diabetes care devices market, holding approximately 41% of the global market share in 2025 . This leadership is driven by several factors: a high prevalence of diabetes in the region, well-established healthcare infrastructure, widespread adoption of advanced technologies like CGMs and insulin pumps, supportive reimbursement policies, and significant healthcare spending . Major companies like Medtronic, Dexcom, Abbott, Tandem Diabetes Care, and Insulet Corporation are headquartered in or have major operations in North America, fueling innovation and rapid product adoption .

However, the competitive landscape is becoming increasingly dynamic. Established global companies are competing with emerging technology innovators, all placing greater emphasis on product innovation, strategic collaborations, and geographic expansion . This competition is accelerating the pace of innovation and bringing new solutions to market faster than ever before.

What Role Do Oral Medications Play Alongside Devices?

While devices are transforming monitoring and insulin delivery, oral medications remain a cornerstone of type 2 diabetes management. These medications are typically prescribed when diet and exercise alone are insufficient to control blood glucose levels . Several classes of oral agents work through different mechanisms to help manage blood sugar:

• Metformin (Biguanides): This first-line treatment reduces glucose production from the liver and is often the initial medication prescribed for type 2 diabetes .
• Thiazolidinediones (Glitazones): These medications enhance glucose removal from the bloodstream, helping cells use insulin more effectively .
• Insulin-Releasing Pills (Sulfonylureas/Secretagogues): These drugs increase insulin release from the pancreas, though they may cause low blood sugar in some patients .
• Starch Blockers (Alpha-Glucosidase Inhibitors): These slow the absorption of sugar from the digestive tract, helping prevent blood sugar spikes after meals .
• Incretin-Based Therapies (Euglycemics): These reduce sugar production in the liver and slow food absorption, offering a dual mechanism of action .

The choice of oral medication depends on the severity of diabetes, the intended use, and other medical conditions . Side effects vary by medication class. For example, sulfonylureas may cause hypoglycemia (low blood sugar) and may not be suitable for people with kidney or liver disease, while metformin may cause gastrointestinal side effects like diarrhea and nausea . Women with gestational diabetes may also need oral agents like metformin if dietary changes and exercise are not enough to keep blood glucose levels within target ranges .

The combination of advanced devices and oral medications, supported by regular blood glucose monitoring and lifestyle changes, creates a comprehensive approach to diabetes management. As the market continues to expand and innovation accelerates, patients have more options than ever to find a management strategy that fits their life. The key is working with your healthcare team to understand which tools and medications are right for your individual situation.